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Asthma: Eosinophil Disease, Mast Cell Disease, or Both?
Peter Bradding, DM, FRCP
Although there is much circumstantial evidence implicating eosinophils as major orchestrators in the pathophysiology of asthma,
recent studies have cast doubt on their importance. Not only does anti-interleukin-5 treatment not alter the course of the disease, but
some patients with asthma do not have eosinophils in their airways, whereas patients with eosinophilic bronchitis exhibit a florid
tissue eosinophilia but do not have asthma. In contrast, mast cells are found in all airways and localize specifically to key tissue
structures such as the submucosal glands and airway smooth muscle within asthmatic bronchi, irrespective of disease severity or
phenotype. Here they are activated and interact exclusively with these structural cells via adhesive pathways and through the release
of soluble mediators acting across the distance of only a few microns. The location of mast cells within the airway smooth muscle
bundles seems particularly important for the development and propagation of asthma, perhaps occurring in response to, and then
serving to aggravate, an underlying abnormality in asthmatic airway smooth muscle function. Targeting this mast cell–airway
smooth muscle interaction in asthma offers exciting prospects for the treatment of this common disease.
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Asthma Immunopathology
Asthma is a complex immunologic and inflammatory
disease characterized by the presence of airway inflamma-
tion, airway wall remodelling, and bronchial hyperrespon-
siveness (BHR). Exactly how these three features interact
and whether they are dependent on each other for their
occurrence is not clear. Although this article focuses on the
role of mast cells and eosinophils in asthma pathogenesis,
it is important to appreciate that most, if not all, elements
of the asthmatic airway are dysfunctional. There is
epithelial damage with failure of healing and overproduc-
tion of growth factors and proinflammatory cytokines,
1
mucous gland hyperplasia with associated mucus hyperse-
cretion,
2 airway smooth muscle (ASM) remodelling with
hypertrophy, hyperplasia, BHR and cytokine secretion,
3–5
and activation of inflammatory cells, including mast cells,
6
T cells,
7 eosinophils,
8 and neutrophils.
2 The current
cornerstone of asthma management is the use of inhaled
corticosteroids, which are efficacious in approximately
90% of patients because they attenuate many of these
diverse pathologic features.
9 However, for the remaining
10% of patients, these drugs are of poor efficacy for
reasons that are not well understood. There is therefore an
unmet clinical need for novel modulators of inflammation
and tissue remodelling with different mechanisms of
action and/or adverse-effect profiles from existing drugs.
A better understanding of the factors orchestrating the
immunopathology of asthma is therefore vital if this is to
be achieved.
Eosinophilic Inflammation in Asthma
It was recognized many years ago in post-mortem studies
that airway mucosal infiltration by eosinophils is a
common feature in patients dying from asthma.
10 More
recently, studies performed on bronchial biopsies obtained
at bronchoscopy demonstrated increased numbers of
eosinophils in the epithelium and lamina propria of even
mild asthmatics when compared with normal subjects.
8,11
The late asthmatic reaction (LAR) following laboratory
allergen challenge is characterized physiologically by
airway narrowing and increased BHR.
12 Accompanying
this is an influx of eosinophils, and it has been proposed
that this eosinophil infiltration contributes to the LAR and
associated physiological abnormalities. In vitro, eosino-
phil-derived major basic protein, eosinophil cationic
protein, and eosinophil peroxidase are cytotoxic to the
respiratory epithelium.
13,14 Elevated levels of these pro-
ducts can be measured in the sputum of asthmatics,
15 in
bronchoalveolar lavage (BAL) fluid,
16 and around areas of
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17 suggesting that air-
way eosinophils are activated and may be an important
mediator of epithelial damage. Eosinophils also release
bronchoconstrictor mediators such as leukotriene C4
(LTC4), which are elevated during the LAR, and more
recently, they have been shown to be a source of numerous
chemokines and cytokines, including interleukin (IL)-4,
18
IL-5,
19 and IL-13,
20 suggesting that they have important
roles in the immunopathology of the disease.
Interestingly, when considering asthma as a whole, the
inflammatory and remodelling changes are remarkably
similar irrespective of how the disease is classified, for
example, atopic, non-atopic, or occupational.
21–24
However, there are clear differences between individual
subjects with asthma that until recently have been
overlooked. It is evident looking at the distribution of
eosinophil counts in Figure 1 that although their numbers
are increased overall in the epithelium and lamina propria
of the steroid-naive asthmatic group, there is a wide range,
and about 25% of subjects have cell counts similar to those
of subjects without asthma.
8 These observations have also
been made in studies looking at induced sputum, where
again about 25% of steroid-naive asthmatic subjects can be
considered to be non-eosinophilic.
25 In severe asthma,
patients can be divided into eosinophil positive or
negative
26 with the presence of mucosal eosinophils plus
neutrophils or neutrophils alone. Interestingly, those
severe patients with a mucosal eosinophilia exhibit
deposition of collagen in the lamina reticularis, whereas
those subjects without eosinophils do not.
26 Thus, in
severe disease, there is heterogeneity in terms of both the
pathology and the inflammatory response. A recent
bronchoscopy study in mild steroid-naive asthmatics
classified as eosinophilic or non-eosinophilic based on
the induced sputum cell profile has revealed similar
findings.
27 These observations indicate that although
eosinophils are often present across the spectrum of
asthma severity, about 25% of patients have active disease
in their absence, so they cannot be an essential require-
ment for disease expression.
Further evidence against a critical role for eosinophils
in day-to-day asthma symptoms has come from studies
with anti-IL-5 antibody treatment.
28–31 Anti-IL-5 anti-
bodies are very effective at reducing sputum and blood
eosinophil counts and redu c et i s s u ee o s i n o p h i l sb y
approximately 60%. However, in spite of this, asthma
symptoms continue unabated, and BHR does not improve.
Furthermore, there is no attenuation of the airway
response to experimental allergen challenge, suggesting
that eosinophils are also not important for this.
29 It has
been argued that a 60% reduction in eosinophils within
the tissue may not be adequate to reduce their pathologic
effects, but this seems unlikely because the reduction in
eosinophils correlates strongly with a reduction in the
deposition of tenascin, lumican, and procollagen III in the
lamina reticularis.
32
Eosinophils, Asthma Exacerbations, and Steroid
Responsiveness
Although the role eosinophils play in the pathophysiology
of asthma is unclear, they represent an excellent biomarker
for predicting whether patients will respond to cortico-
steroids, predicting which patients are at risk of exacerba-
tions, and for guiding steroid therapy with a view to
preventing these events. Several studies have shown that
steroid-naive asthmatic patients with a sputum eosinophi-
lia have an excellent clinical response to inhaled cortico-
steroids, whereas non-eosinophilic patients do not.
25,27
The presence of eosinophils is also a good predictor of
whether a patient is at risk of asthma exacerbations, and
keeping the sputum eosinophil count suppressed through
the appropriate use of inhaled or oral corticosteroids
reduces the number of severe exacerbations in patients
with severe disease by about 60%.
33 Whether eosinophils
play a role in the pathophysiology of acute exacerbations is
still not known as the previous anti-IL-5 studies were not
powered to test this. There was a non-significant trend
toward reduced asthma exacerbations in one anti-IL-5
trial.
31 A further ongoing clinical trial limited to patients
Figure 1. Eosinophil counts in the bronchial epithelium and lamina
propria in normal subjects (N) and patients with mild steroid-naive
asthma (A). Adapted from Bradding P et al.
8
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IL-5 on asthma exacerbations as the primary end point.
Mast Cells in Asthma
Mast cells have long been considered to play a significant
role in the pathophysiology of asthma through their ability
to release a host of pleiotropic autacoid mediators,
proteases, and cytokines in response to activation by both
immunoglobulin E (IgE)-dependent and diverse non-
immunologic stimuli.
6,34 Within the first few minutes
following laboratory allergen challenge, secretion of the
autacoid mediators histamine, prostaglandin D2 (PGD2)
and LTC4 induces bronchoconstriction, mucus secretion,
and mucosal edema, which account for the acute
symptoms.
35 Mast cells also release preformed and newly
generated cytokines with the potential for a wide range of
biological effects in the airways. For example, these include
IL-4 and IL-13, which both induce ASM hyperresponsive-
ness, IgE synthesis, and eosinophil recruitment, and IL-5,
an important eosinophil growth factor.
6 In addition, the
mast cell is a source of several neutral proteases, such as
tryptase and chymase, which interact with many cells and
potentially contribute to airway wall remodelling.
6
Tumour necrosis factor a (TNF-a) is another proinflam-
matory cytokine secreted by mast cells that is strongly
implicated in the pathogenesis of asthma. TNF-a expres-
sion is increased in the airways of both mild and severe
asthmatics,
8,36 largely owing to increased expression by
mucosal mast cells. When administered by inhalation to
humans, it induces both BHR and sputum neutrophilia in
normal subjects and exacerbates BHR in patients with
asthma,
37,38 whereas anti-TNF-a therapy is effective
treatment in some patients with refractory disease.
36,39
In chronic asthma, mast cells within the bronchial
mucosa are persistently activated with evidence of
continuous mediator release and cytokine synthe-
sis.
11,16,23,40 This is apparent from increased concentra-
tions of mast cell–specific mediators such as tryptase in
BAL, increased cell-associated cytokine messenger ribonu-
cleic acid and protein expression, and degranulation
visualized in situ using electron microscopy. It is often
assumed that this activation is driven by allergen, but it is
important to appreciate that mast cells can be activated by
numerous diverse stimuli, including monomeric IgE
alone,
34 proteases (including tryptase),
41,42 cytokines (eg,
stem cell factor, TNF-a, interferon-c),
43–45 complement
(C5a),
46 Toll-like receptor ligands,
45,47,48 immunoglobulin
light chains,
49 and hyperosmolality
50 (Figure 2). Many of
these are relevant to the complex inflammatory milieu of
the asthmatic airway. Furthermore, the ultrastructural
appearance of mast cells in asthmatic airways often
indicates a process of piecemeal degranulation rather than
the anaphylactic degranulation evident after allergen
challenge.
11 This supports the view that allergen-indepen-
dent mechanisms of mast cell activation are important.
Mast Cell Tissue Microlocalization in Asthma
Mast cells are found adjacent to blood vessels in the lamina
propria in normal human airways, but in asthma, they
migrate into three key structures: the airway epithelium,
8
the airway mucous glands,
2 and the ASM.
51 This
anatomical relocation places activated mast cells deep
within these dysfunctional airway elements, suggesting that
the targeted delivery of their mediators is likely to be
central to the disordered airway physiology.
Infiltration of the bronchial epithelium by mast cells in
asthma may be important for disease pathogenesis for
several reasons. First, mast cells are placed at the portal of
entry of noxious stimuli such as aeroallergens, which
might facilitate an effector role in the ongoing immuno-
logic response (antigen presentation, T-helper 2 [Th2] cell
differentiation, IgE synthesis).
52 Second, there are likely to
be important consequences of mast cell degranulation on
epithelial function. For example, mast cells adhere avidly
to bronchial epithelial cells,
53 and tryptase stimulates
airway epithelial IL-8 release and can upregulate inter-
cellular adhesion molecule 1 expression.
54 At this site, mast
cells might also respond more readily to other stimuli, for
example, hyperosmolarity of the airway lining fluid
induced by exercise, or inhaled bronchoconstrictors, such
as adenosine. Interestingly, monolayers of bronchial
epithelium actually inhibit IgE-dependent human lung
mast cell mediator release.
55 Thus, resting intact airway
epithelium may act as a suppressor of mast cell activation,
an effect that is lost when the airway epithelium is
damaged.
Severe mucus plugging is a well-known feature of
severe fatal asthma but is also recognized as a feature of
milder disease
2,56 and results from mucus hypersecretion
by hyperplastic submucosal glands and epithelial goblet
cells. Mast cells specifically infiltrate the mucosal gland
stroma in asthma and exhibit features of degranulation.
2
Their numbers also correlate with the degree of mucus
obstruction in the airways. Taken together, this suggests a
role for mast cells in the development of mucous gland
hyperplasia and the mucous gland hypersecretion char-
acteristic of asthma. Numerous mast cell products are
likely to contribute to these features of asthma, including
86 Allergy, Asthma, and Clinical Immunology, Volume 4, Number 2, 2008histamine, PGD2, LTC4, IL-6, IL-13, TNF-a, tryptase,
chymase, and amphiregulin.
6
Mast Cell Infiltration of the ASM as a Key
Determinant of the Asthmatic Phenotype:
Pathologic Comparison of Asthma with Eosinophilic
Bronchitis
Eosinophilic bronchitis is a common cause of cough and is
characterized by the presence of a sputum eosinophilia
occurring in the absence of variable airflow obstruction or
BHR.
57 A detailed comparison of the immunopathology of
asthma and eosinophilic bronchitis has revealed an
identical pathology in terms of T-cell and eosinophil
infiltration, mucosal mast cell density, Th2 cytokine
expression, epithelial integrity, sub-basement membrane
collagen deposition, and mediator concentrations, includ-
ing histamine and PGD2.
51,58,59 This suggests that many of
the immunopathologic features previously attributed to
causing asthma may not be as important for the
development of airflow obstruction, BHR, and remodel-
ling as previously suggested. It also demonstrates that it is
possible to have florid eosinophilic airway inflammation in
the absence of asthma.
The striking difference between the pathology of
asthma and eosinophilic bronchitis is present within the
ASM bundles. In asthmatic subjects, there are numerous
mast cells within the ASM, but these are rarely seen in the
ASM of patients with eosinophilic bronchitis or normal
subjects.
51 The majority of these mast cells are of the MCTC
phenotype containing both tryptase and chymase. The
number of mast cells in the ASM bundles correlates with
the severity of BHR within the asthmatic group, support-
ing the view that this observation is of functional
relevance. Our initial study failed to identify T cells or
eosinophils in the smooth muscle of any of the study
groups, although a more recent study has claimed to
identify the presence of some T cells.
60 The findings related
to mast cells have been confirmed by several independent
groups,
60–64 and it has recently been shown that the mast
cells within the ASM bundles in asthma demonstrate
ultrastructural features of activation.
60 We have also
extended our work to look across asthma phenotypes.
Interestingly, ASM infiltration by mast cells is a feature of
both eosinophilic and non-eosinophilic asthma, again
Figure 2. Potential mechanisms of
mast cell activation in asthmatic air-
ways.
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in asthma.
27
Functional Consequences of ASM Infiltration by
Mast Cells
Human lung mast cells adhere to ASM cells,
65 in part
through the immunoglobulin superfamily member cell
adhesion molecule 1 (previously known as tumour
suppressor in lung cancer 1). This, coupled with the
observation that mast cells within the ASM bundles are
activated, suggests that there is an intimate relationship
between the two cell types. Numerous mast cell–derived
mediators directly affect ASM function both in vitro and
in vivo. Histamine, PGD2 and LTC4 are all potent agonists
for ASM contraction, whereas tryptase potentiates the
contractile response of sensitized bronchi to histamine
66
and induces proliferation of human ASM.
67,68 IL-4 and IL-
13 induce BHR when instilled into the airways of mice,
69
and of note, both of these cytokines are expressed by mast
cells within the asthmatic ASM.
70 Several potential
mechanisms for the recruitment of mast cells by the
ASM have been identified,
5,62,71 but the CXCL10-CXCR3
axis looks particularly important.
5,71 Targeting mast cell
migration through these specific chemokine pathways or
through a more generalized approach
72 may therefore
provide a novel means for inhibiting the interaction of
mast cells with the ASM.
In summary, although there is much circumstantial
evidence implicating eosinophils as major orchestrators in
the pathophysiology of asthma, recent studies have cast
doubt on their importance. Not only does anti-IL-5
treatment not alter the course of the disease, but some
patients with asthma do not have eosinophils in their
airways, whereas patients with eosinophilic bronchitis
exhibit a florid tissue eosinophilia but do not have asthma.
In contrast, mast cells are found in all airways and localize
specifically to key tissue structures, such as the submucosal
glands and ASM within asthmatic bronchi, irrespective of
disease severity or phenotype. Here they are activated and
interact exclusively with these structural cells via adhesive
pathways and through the release of soluble mediators
acting across the distance of only a few microns. The
location of mast cells within the ASM bundles seems
particularly important for the development and propaga-
tion of asthma, perhaps occurring in response to, and then
serving to aggravate, an underlying abnormality in the
behaviour of asthmatic ASM. Targeting this mast cell–
ASM interaction in asthma offers exciting prospects for the
treatment of this common disease.
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